Cost effectiveness of the type II Boston keratoprosthesis

PURPOSE: Despite demonstrated cost effectiveness, not all corneal disorders are amenable to type I Boston keratoprosthesis (KPro) implantation. This includes patients with autoimmune diseases, such as Stevens–Johnson syndrome/toxic epidermal necrolysis. Type II KPro is implanted through the eyelids...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ament, J D, Stryjewski, T P, Pujari, S, Siddique, S, Papaliodis, G N, Chodosh, J, Dohlman, C H
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2011
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3178310/
https://ncbi.nlm.nih.gov/pubmed/21183944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/eye.2010.197
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars